No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Raises Target Price to $102
Express News | Keros Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $102
Keros Therapeutics Initiated at Outperform by Oppenheimer
Express News | Oppenheimer Initiates Coverage On Keros Therapeutics With Outperform Rating, Announces Price Target of $102
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long